Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

cystic fibrosis, Alzheimer’s, Duchnene muscular dystrophy (DMD), and other chronic musculoskeletal disorders. The FDA recently approved CRISPR to treat sickle cell disease, an inherited disorder ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Cystic fibrosis (CF) is a life-threatening genetic ... The team developed their CF rabbit model using CRISPR/Cas9 gene-editing technology. Rabbits with CF exhibited hallmark pancreatic changes ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...